CODE: 7.1 - The effect of LHRH analogue treatment on chosen cytokine profile in prostatic cancer patients
Article published in Urologia Polska 2006/59/Suplement 1.

authors

Piotr Kaczmarek ¹, Lech Pokoca ¹, Jerzy Niemirowicz ², Konrad Jersak ², Zbigniew Baj ¹

¹ Zakład Patofizjologii i Immunologii Klinicznej UM w Łodzi
² Oddział Urologii Szpitala MSWiA w Łodzi

summary

Introduction. LHRH analogue therapy constitutes essential way of pharmacological castration. Its action is based on decrease in production of testosterone. The relation between immunological and endocrine system is well known. The immunological effect of LHRH therapy in Pca patients is a matter of debate.

Objectives. The aim of our examination was to test aIL-10, TNF-a, Il-2, INF-g levels in patients with prostate cancer treated with LHRH analogues.

Materials and methods. The study comprised 11 men with prostate cancer treated with LHRH analogue, average age 77.4 years. Patients had monthly one depot injection of LHRH analogue. Material for examination - venous blood was collected at three time points 1- before injection, 2 - after 10 days and 3-20 days after injection. In serum samples the cytokines were determined by ELISA method. The test reading was done with the aid of optical density reading apparatus with software.

Results. IL-2 concentration value was 29.736 pg/ml. In the second probe it decreased significantly to 7.067 (p<0.005) and then increased to - 13.348 pg/ml. IL-10 level dropped significantly (p<0.07) from 5.58 pg/ml to 3.68 pg/ml at the third time point. Blood serum INF-g and TNF-a did not change significantly.

Conclusions. LHRH analogue treatment in prostate cancer patients may have transient immunosuppressive effect.